Skip to main content
SpringerLink
Log in

Emtricitabine/tenofovir alafenamide not cost effective despite fewer AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 US dollars

  2. 2018 US dollars

References

  • 1. Walensky RP, et al. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Annals of Internal Medicine : 10 Mar 2020. Available from: URL: http://doi.org/10.7326/M19-3478

  • 2. del Rio C, et al. How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States? Annals of Internal Medicine : 10 Mar 2020. Available from: URL: http://dx.doi.org/10.7326/M20-0799

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Emtricitabine/tenofovir alafenamide not cost effective despite fewer AEs. Reactions Weekly 1796, 8 (2020). https://doi.org/10.1007/s40278-020-76295-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-76295-7

Search

Navigation